Owlstone Medical (“Owlstone”), the worldwide chief in Breath Biopsy® for purposes in early illness detection and precision medication, at this time introduced that it has entered right into a Analysis Settlement with Bicycle Therapeutics plc (NASDAQ: BCYC, “Bicycle”), a biotechnology firm pioneering a brand new and differentiated class of therapeutics primarily based on its proprietary bicyclic peptide (Bicycle®) expertise.
Underneath the Settlement, the Firms will examine the potential of mixing applied sciences and strategies to develop antigen-targeted diagnostic probes that use bicyclic peptides as their focusing on mechanism linked with Owlstone’s Exogenous Unstable Natural Compound (EVOC®) Probes. Work will initially give attention to lung most cancers screening as the primary proof of precept for the broader alternative by selling selective accumulation of the probe on the tumor for elevated sign and enhanced specificity.
If profitable, the ensuing antigen-targeted EVOC Probes can have the potential to be used in pre-clinical analysis to help each cell-based and in-vivo research; in scientific trials for affected person stratification and measurement of goal engagement; and as companion diagnostics to determine responders/non-responders for remedy choice and to measure goal engagement over the course of remedy.
Owlstone is growing diagnostic exams in areas of excessive unmet scientific want together with for the early detection of lung most cancers, the commonest most cancers on the earth. To help this effort, Owlstone has pioneered using EVOC Probes1 in early detection and precision medication, with the Firm’s lead EVOC Probe in scientific trials. This probe makes use of the exercise of enzymes expressed throughout the tumor microenvironment to launch a unstable reporter chemical that may be detected on breath when a tumor is current. The mixed method to be explored below the Settlement will exploit Bicycle’s proprietary Bicycle expertise to direct binding and accumulation of the probe on tumor cells, following which elevated ranges of the reporter chemical could be launched.
“We’re dedicated at Owlstone to reworking diagnostics via the sooner detection of illness via breath, and are all the time searching for modern approaches to additional improve the efficiency of our exams. By means of our partnership with Bicycle, we’ll collectively discover the thrilling prospects of a mixed antigen-targeted EVOC method for a broad vary of precision medication purposes, initially for the early detection of lung most cancers to help Owlstone’s ongoing work on this space.”
Billy Boyle, co-founder and CEO at Owlstone Medical
